Timber Pharma: Up on early patient enrollment completion for genetic disorder trial

Trex Wind-Down

27/05/2021 11:32

** Shares of drug developer  TMBR.A  rise 10.7% to $1.34
premarket; among top pct gainers across U.S. exchanges
    ** Co said on Wednesday it will complete patient enrollment
early on May 31 in a mid-stage trial testing its treatment
TMB-001 for congenital ichthyosis  urn:newsml:reuters.com:*:nGNE3V521B
    ** Plans for an end of mid-stage trial meetings with the
U.S. FDA by end of 2021
    ** Expects to announce results from the Phase 2b trial in Q4
    ** Congenital ichthyosis is a group of rare genetic
keratinization disorders that lead to dry, thickened, and
scaling skin
    ** Stock up ~63% YTD

 (Reporting by Trisha Roy in Bengaluru)
 ((Trisha.Roy@thomsonreuters.com; within U.S. +1 646 223 8780,
outside U.S. +91 80 6182 3635;))